Lilly Xigris Action Date Is Oct. 27; FDA Preparing For Advisory Cmte. Review
Executive Summary
The FDA user fee action date for Lilly's sepsis therapy Xigris (formerly Zovant) is extended until Oct. 27.
You may also be interested in...
Icos Pafase Phase III Sepsis Trial Will Collect Cost-Effectiveness Data
Icos will collect cost-effectiveness data in the Phase III trial for its sepsis treatment Pafase (recombinant platelet activating factor acetylhydrolase).
Icos Pafase Phase III Sepsis Trial Will Collect Cost-Effectiveness Data
Icos will collect cost-effectiveness data in the Phase III trial for its sepsis treatment Pafase (recombinant platelet activating factor acetylhydrolase).
Orphan Medical Xyrem FDA Study Request Could Delay Launch Until Mid-2002
Orphan Medical's launch for its narcoleptic cataplexy treatment Xyrem could be delayed until mid-2002 by an FDA request for a study of respiratory-compromised patients.